Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice

Keiichi Kodama, Akira Shimada, Osamu Funae, Jiro Morimoto, Junichiro Irie, Toshikatsu Shigihara, Yoichi Oikawa, Mikiya Tokui, Kenji Watanabe, Takao Saruta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Spontaneous diabetes in non-obese diabetic (NOD) mice results from β-cell destruction by autoreactive T lymphocytes. Here, we report the significance of insulin-like growth factor-1 (IGF-1) peptide as a tool for the prevention of type 1 diabetes. Female NOD mice were immunized with a subcutaneous injection of IGF-1, glutamic acid decarboxylase (GAD), insulin or IGF-1-derived peptides (residues 8-23, 24-41 or 50-70) in incomplete Freund's adjuvant (IFA) or with IFA only as the control group at 4 weeks of age, and observed up to 36-37 weeks of age. Diabetes onset was significantly suppressed and delayed in the IGF-1 group as compared to the GAD, insulin and control groups (p < 0.05), and it was significantly suppressed and delayed in the (50-70)IGF-1 group as compared to the (8-23)IGF-1 and control groups (p < 0.02). Although the degree of insulitis in all treated mice was not significantly different, a significant number of IL-4-producing cells in response to IGF-1 peptides were detected in (50-70)IGF-1-treated mice in intracellular cytokine assay. In conclusion, IGF-1 peptide 50-70 immunizations of NOD mice suppressed and delayed diabetes onset, probably through amplification of the Th2-type response. It was suggested that IGF-1 peptide 50-70 immunization can be used as a tool for prevention of type 1 diabetes.

Original languageEnglish
Pages (from-to)481-487
Number of pages7
JournalAutoimmunity
Volume37
Issue number6-7
DOIs
Publication statusPublished - 2004 Sep

Fingerprint

Inbred NOD Mouse
Somatomedins
Peptides
Glutamate Decarboxylase
Type 1 Diabetes Mellitus
Control Groups
Immunization
Insulin
Subcutaneous Injections
Interleukin-4
Cytokines
T-Lymphocytes

Keywords

  • Antigen
  • IGF-1
  • NOD mouse
  • Peptide therapy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kodama, K., Shimada, A., Funae, O., Morimoto, J., Irie, J., Shigihara, T., ... Saruta, T. (2004). Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice. Autoimmunity, 37(6-7), 481-487. https://doi.org/10.1080/08916930400001909

Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice. / Kodama, Keiichi; Shimada, Akira; Funae, Osamu; Morimoto, Jiro; Irie, Junichiro; Shigihara, Toshikatsu; Oikawa, Yoichi; Tokui, Mikiya; Watanabe, Kenji; Saruta, Takao.

In: Autoimmunity, Vol. 37, No. 6-7, 09.2004, p. 481-487.

Research output: Contribution to journalArticle

Kodama, K, Shimada, A, Funae, O, Morimoto, J, Irie, J, Shigihara, T, Oikawa, Y, Tokui, M, Watanabe, K & Saruta, T 2004, 'Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice', Autoimmunity, vol. 37, no. 6-7, pp. 481-487. https://doi.org/10.1080/08916930400001909
Kodama, Keiichi ; Shimada, Akira ; Funae, Osamu ; Morimoto, Jiro ; Irie, Junichiro ; Shigihara, Toshikatsu ; Oikawa, Yoichi ; Tokui, Mikiya ; Watanabe, Kenji ; Saruta, Takao. / Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice. In: Autoimmunity. 2004 ; Vol. 37, No. 6-7. pp. 481-487.
@article{7ee1d7750f08472c91561835d4608ae9,
title = "Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice",
abstract = "Spontaneous diabetes in non-obese diabetic (NOD) mice results from β-cell destruction by autoreactive T lymphocytes. Here, we report the significance of insulin-like growth factor-1 (IGF-1) peptide as a tool for the prevention of type 1 diabetes. Female NOD mice were immunized with a subcutaneous injection of IGF-1, glutamic acid decarboxylase (GAD), insulin or IGF-1-derived peptides (residues 8-23, 24-41 or 50-70) in incomplete Freund's adjuvant (IFA) or with IFA only as the control group at 4 weeks of age, and observed up to 36-37 weeks of age. Diabetes onset was significantly suppressed and delayed in the IGF-1 group as compared to the GAD, insulin and control groups (p < 0.05), and it was significantly suppressed and delayed in the (50-70)IGF-1 group as compared to the (8-23)IGF-1 and control groups (p < 0.02). Although the degree of insulitis in all treated mice was not significantly different, a significant number of IL-4-producing cells in response to IGF-1 peptides were detected in (50-70)IGF-1-treated mice in intracellular cytokine assay. In conclusion, IGF-1 peptide 50-70 immunizations of NOD mice suppressed and delayed diabetes onset, probably through amplification of the Th2-type response. It was suggested that IGF-1 peptide 50-70 immunization can be used as a tool for prevention of type 1 diabetes.",
keywords = "Antigen, IGF-1, NOD mouse, Peptide therapy, Type 1 diabetes",
author = "Keiichi Kodama and Akira Shimada and Osamu Funae and Jiro Morimoto and Junichiro Irie and Toshikatsu Shigihara and Yoichi Oikawa and Mikiya Tokui and Kenji Watanabe and Takao Saruta",
year = "2004",
month = "9",
doi = "10.1080/08916930400001909",
language = "English",
volume = "37",
pages = "481--487",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "6-7",

}

TY - JOUR

T1 - Insulin-like growth factor-1 (IGF-1)-derived peptide protects against diabetes in NOD mice

AU - Kodama, Keiichi

AU - Shimada, Akira

AU - Funae, Osamu

AU - Morimoto, Jiro

AU - Irie, Junichiro

AU - Shigihara, Toshikatsu

AU - Oikawa, Yoichi

AU - Tokui, Mikiya

AU - Watanabe, Kenji

AU - Saruta, Takao

PY - 2004/9

Y1 - 2004/9

N2 - Spontaneous diabetes in non-obese diabetic (NOD) mice results from β-cell destruction by autoreactive T lymphocytes. Here, we report the significance of insulin-like growth factor-1 (IGF-1) peptide as a tool for the prevention of type 1 diabetes. Female NOD mice were immunized with a subcutaneous injection of IGF-1, glutamic acid decarboxylase (GAD), insulin or IGF-1-derived peptides (residues 8-23, 24-41 or 50-70) in incomplete Freund's adjuvant (IFA) or with IFA only as the control group at 4 weeks of age, and observed up to 36-37 weeks of age. Diabetes onset was significantly suppressed and delayed in the IGF-1 group as compared to the GAD, insulin and control groups (p < 0.05), and it was significantly suppressed and delayed in the (50-70)IGF-1 group as compared to the (8-23)IGF-1 and control groups (p < 0.02). Although the degree of insulitis in all treated mice was not significantly different, a significant number of IL-4-producing cells in response to IGF-1 peptides were detected in (50-70)IGF-1-treated mice in intracellular cytokine assay. In conclusion, IGF-1 peptide 50-70 immunizations of NOD mice suppressed and delayed diabetes onset, probably through amplification of the Th2-type response. It was suggested that IGF-1 peptide 50-70 immunization can be used as a tool for prevention of type 1 diabetes.

AB - Spontaneous diabetes in non-obese diabetic (NOD) mice results from β-cell destruction by autoreactive T lymphocytes. Here, we report the significance of insulin-like growth factor-1 (IGF-1) peptide as a tool for the prevention of type 1 diabetes. Female NOD mice were immunized with a subcutaneous injection of IGF-1, glutamic acid decarboxylase (GAD), insulin or IGF-1-derived peptides (residues 8-23, 24-41 or 50-70) in incomplete Freund's adjuvant (IFA) or with IFA only as the control group at 4 weeks of age, and observed up to 36-37 weeks of age. Diabetes onset was significantly suppressed and delayed in the IGF-1 group as compared to the GAD, insulin and control groups (p < 0.05), and it was significantly suppressed and delayed in the (50-70)IGF-1 group as compared to the (8-23)IGF-1 and control groups (p < 0.02). Although the degree of insulitis in all treated mice was not significantly different, a significant number of IL-4-producing cells in response to IGF-1 peptides were detected in (50-70)IGF-1-treated mice in intracellular cytokine assay. In conclusion, IGF-1 peptide 50-70 immunizations of NOD mice suppressed and delayed diabetes onset, probably through amplification of the Th2-type response. It was suggested that IGF-1 peptide 50-70 immunization can be used as a tool for prevention of type 1 diabetes.

KW - Antigen

KW - IGF-1

KW - NOD mouse

KW - Peptide therapy

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=19944428998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428998&partnerID=8YFLogxK

U2 - 10.1080/08916930400001909

DO - 10.1080/08916930400001909

M3 - Article

C2 - 15621575

AN - SCOPUS:19944428998

VL - 37

SP - 481

EP - 487

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 6-7

ER -